Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.…
Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics (NASDAQ: INDP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 2.820 USD on 20 November 2026, up 11.0% over 52 weeks. Its 52-week range is 0.9200 USD to 5.960 USD: the price is 52.7% below the high and 206.5% above the low.
Its market capitalisation is 433.16M USD.
Indaptus Therapeutics reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 11.55M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.